Core Viewpoint - The article discusses the rise and challenges faced by Juzhi Biotechnology, highlighting its rapid growth in the beauty industry and the recent controversies surrounding its flagship product, the collagen stick. Group 1: Company Overview - Juzhi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, with a market value exceeding 450 billion yuan in May 2023, making them the richest couple in Shaanxi [1][2]. - The company specializes in recombinant collagen products, leveraging advanced biotechnology to create products that mimic human collagen [5][6]. Group 2: Recent Controversies - In May 2023, Juzhi Biotechnology faced backlash from competitors and influencers, particularly regarding the safety and authenticity of its collagen stick product [3][11]. - A beauty influencer claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [11][14]. - Juzhi Biotechnology responded by asserting that their products met industry standards and were undergoing third-party testing to verify their claims [14][16]. Group 3: Market Impact - Following the controversies, Juzhi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [3][19]. - The company has seen significant sales from its collagen stick, generating over 5.15 billion yuan in revenue since its launch, accounting for 82% of the company's total revenue in 2024 [16][19]. Group 4: Competitive Landscape - The article highlights the competitive tension between Juzhi Biotechnology and other industry players, particularly Huaxi Biological, which criticized Juzhi's marketing tactics and product claims [3][19]. - Both companies have invested heavily in marketing, with Juzhi's marketing expenses exceeding 2 billion yuan in 2024, while Huaxi's were around 24.64 billion yuan [19].

Core Viewpoint - The company, Giant Biological, has issued a strong statement denying allegations of product fraud related to its brand, Kefu Mei, specifically regarding the collagen content in its products. The company asserts that all products comply with regulatory standards and have undergone rigorous testing to ensure quality and safety [4][8]. Group 1: Company Response - Giant Biological firmly rejects accusations of serious fraud and insists that all product formulations are accurately labeled and compliant with relevant regulations [4][6]. - The company conducted multiple tests on its products, confirming that the collagen content exceeds 0.1%, contradicting claims of a mere 0.0177% [5][6]. - A detailed report of the testing results shows collagen content in various batches of the product, with values ranging from 0.27% to 0.28% [5]. Group 2: Allegations and Background - The controversy began when a social media account, "Big Mouth Doctor Yan Research Institute," published an article questioning the authenticity of Giant Biological's collagen products, claiming they lacked essential amino acids [9][10]. - The article's author, who claims to be a PhD from the University of Hong Kong, used high-precision HPLC methods to assert that the collagen content was significantly lower than advertised [10][14]. - The allegations have sparked widespread industry attention and concern regarding the integrity of the collagen market [9][10]. Group 3: Financial Performance - Giant Biological reported a revenue of 5.539 billion yuan for 2024, marking a year-on-year increase of 57.17%, with a net profit of 2.062 billion yuan, up 42.06% [25]. - The company's revenue is primarily driven by its professional skincare and health food segments, with its two main brands, Kefu Mei and Keli Jin, generating over 50 billion yuan, accounting for 97.2% of total revenue [25]. Group 4: Market Impact - Following the allegations, Giant Biological's stock price fell by 5.72%, with a market capitalization of 821.38 billion HKD as of May 23 [26].

Core Viewpoint - The recent discussions surrounding hyaluronic acid and recombinant collagen in the medical beauty industry have intensified, particularly following Huaxi Biological's publications defending hyaluronic acid's relevance and efficacy over recombinant collagen [1][4][5]. Group 1: Company Response and Market Dynamics - Huaxi Biological has issued statements refuting claims that hyaluronic acid is outdated, emphasizing the importance of both hyaluronic acid and collagen in skin health, and their interdependent roles in extracellular matrix (ECM) function [4][5]. - The company highlighted that it holds the highest number of approved Class III medical device certifications for hyaluronic acid products, asserting that there is no evidence to suggest that recombinant collagen is safer than hyaluronic acid [5]. - The shift in market focus from hyaluronic acid to recombinant collagen has led to a decline in the stock prices and performance of traditional hyaluronic acid companies, while recombinant collagen firms have seen significant gains [6]. Group 2: Financial Performance - Huaxi Biological reported a revenue decline of 11.61% year-on-year, with total revenue of approximately 5.371 billion yuan and a net profit drop of 70.59%, amounting to about 174 million yuan for 2024 [6][7]. - The company’s medical beauty segment showed positive growth, with raw material business revenue increasing by 9.47% to 1.236 billion yuan, while the medical terminal business grew by 32.03% to 1.44 billion yuan [7]. - The significant decline in overall performance was attributed to challenges in the consumer goods segment, which faced intensified competition and strategic adjustments, resulting in a 31.62% revenue drop to 2.569 billion yuan [7]. Group 3: Management Changes and Corporate Governance - In response to internal issues, Huaxi Biological has initiated a major management reform, focusing on addressing corruption and improving corporate governance, with a strict deadline for employees to report any misconduct [9][10]. - The company has undergone significant personnel changes, including the retirement of senior executives and the appointment of new management to align with strategic development needs [10]. - The management reform aims to correct previous lax practices and establish a more robust operational framework for long-term growth [9].

Group 1: Industry Initiatives - The China Fragrance and Cosmetic Industry Association and the China Association of Plastic Surgery jointly released a health ecosystem initiative for the medical beauty and cosmetics industry, emphasizing the importance of scientific rigor and rational guidance in product efficacy [1] - The initiative calls for promoting public understanding through scientific education and collaboration with authoritative institutions to enhance public awareness of technological paths [1] - It advocates for innovation and diversity in the industry, encouraging cooperation in ingredient innovation, formula optimization, and process breakthroughs [1] - The initiative stresses the need for civilized marketing and honest promotion, aiming to establish objective and fair marketing practices as industry norms [1] - It proposes the establishment of an industry self-discipline system and a self-discipline alliance to evaluate and publicly disclose results of any misleading or uncivil behavior [1] Group 2: Company Positioning - Huaxi Biological published an article addressing misleading conclusions regarding the comparison between collagen and hyaluronic acid, which have been widely circulated in the media [2] - The company clarified that its concerns about collagen products primarily relate to the exaggerated claims of topical collagen skincare products, emphasizing that effective collagen products require injection [2][3] - Huaxi Biological's strategy focuses on leveraging hyaluronic acid to develop synthetic biological capabilities, exploring effective substances in life sciences, while maintaining a unified strategic logic [3] - The company has not promoted collagen as a mainstream technology in consumer products due to insufficient scientific evidence supporting its efficacy in managing aging compared to hyaluronic acid [3] - Huaxi Biological believes that the extracellular matrix (ECM) is the comprehensive research and industrial transformation direction that includes all key substances like hyaluronic acid, collagen, and elastin [3]

4月28日，由山东轻工业联合会组织的科技成果鉴定会在山东福瑞达（600223）生物股份（600201）有 限公司成功举行。鉴定会邀请来自生物医药、化妆品科学、微生物学等领域的权威专家组成鉴定委员 会，经专家委员会评定，"功能性皮肤菌的研究及功能护理产品开发"与"透明质酸锌的制备及其在护肤 品中的应用研究"两项科学技术成果分别获得"国际领先"及"国际先进"水平，标志着企业科研实力获得 了国内权威学术组织的高度认可。 福瑞达颐莲品牌研发经理王晓娜就"透明质酸锌的制备及其在护肤品中的应用研究"项目汇报了技术研究 报告。该项目历经5年研发历程，突破了高效制备透明质酸锌的技术瓶颈，并系统研究了透明质酸锌多 维度的功能机制，高效靶向抑制5α-还原酶并建立其国内首个检测标准，创新适配开发护肤品、发用产 品及彩妆产品，拓展了透明质酸锌的多领域应用。在技术成果方面，项目已发表科技论文2篇，获授权 发明专利3项。专家组认为，该项目的研究填补了透明质酸锌成分在精准控油舒缓护肤方向研究的空 白，为透明质酸衍生物的研究及化妆品领域的科学创新起到了积极推进作用。 "功能性皮肤菌的研究及功能护理产品开发"是福瑞达瑷尔博士品牌建设的皮肤微生 ...